Publications by authors named "Steven Deitcher"

Claim this Profile
H
High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
Olivia R Deitcher, John Glaspy, Rene Gonzalez, Takami Sato, Agop Y Bedikian, Steven R Deitcher

Clin Lymphoma Myeloma Leuk· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.
Lawrence D Kaplan, Steven R Deitcher, Jeffrey A Silverman, Gareth Morgan

Clin Lymphoma Myeloma Leuk· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Jeffrey A Silverman, Laurie Reynolds, Steven R Deitcher

J Clin Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, Anas Younes, Luis Fayad

Br J Haematol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
Jeffrey A Silverman, Steven R Deitcher

Cancer Chemother Pharmacol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
Susan O'Brien, Gary Schiller, John Lister, Lloyd Damon, Stuart Goldberg, Steven R Deitcher

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Deborah A Thomas, Hagop M Kantarjian, Wendy Stock, Leonard T Heffner, Stefan Faderl, Steven R Deitcher

Cancer· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
M A Rodriguez, Robert Pytlik, Tomas Kozak, Mukesh Chhanabhai, Randy Gascoyne, Steven R Deitcher

Cancer· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Agop Y Bedikian, Nicholas E Papadopoulos, Kevin B Kim, Anna Vardeleon, Teresa Smith, Steven R Deitcher

Melanoma Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To clot or not to clot: are there predictors of clinically significant thrombus formation in patients with gastroparesis and prolonged IV access?
W Bradley Creel, Thomas L Abell, Amy Lobrano, Steven R Deitcher, M Dugdale

Dig Dis Sci· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.
Robert P Giugliano, Stephen D Wiviott, Peter H Stone, Daniel I Simon, Marc J Schweiger, Steven R Deitcher

J Am Coll Cardiol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience.
Sanjay Rajagopalan, Jeffrey Olin, Steven Deitcher, Ann Pieczek, John Laird

Circulation· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Eric Jorgenson, Steven R Deitcher, Mine Cicek, Xin Liu, Sarah Plummer

Prostate· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alfimeprase: a novel recombinant direct-acting fibrinolytic.
Steven R Deitcher, Walter D Funk, James Buchanan, Shouchun Liu, Michael D Levy

Expert Opin Biol Ther· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Steven R Deitcher, Craig M Kessler, Geno Merli, James R Rigas, Roger M Lyons

Clin Appl Thromb Hemost· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase.
Steven R Deitcher, Christopher F Toombs

Pathophysiol Haemost Thromb· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
Stephan Moll, Peter Kenyon, Luigi Bertoli, James De Maio, Howard Homesley, Steven R Deitcher

J Clin Oncol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis.
Gordan Srkalovic, Marte G Cameron, Steven R Deitcher, Kandice Kattke-Marchant, Mohamad A Hussein

Int Semin Surg Oncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of alfimeprase for peripheral arterial thrombolysis.
Kenneth Ouriel, Jacob Cynamon, Fred A Weaver, Herbert Dardik, Donald Akers, Steven R Deitcher

J Vasc Interv Radiol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of enoxaparin at the cremaster muscle flap microcirculation.
Nilgün Markal Ertaş, Corey Goldman, Steven Deitcher, Maria Siemionow

Microsurgery· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia.
Gustavo A Cardenas, Steven R Deitcher

Mayo Clin Proc· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically evident venous thromboembolic events in children with brain tumors.
Steven R Deitcher, Amar Gajjar, Larry Kun, Richard L Heideman

J Pediatr· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of thromboembolism and role of low molecular weight heparin in prolonging survival in patients with advanced malignancies.
G Kesava Reddy, Vinay K Jain, Steven Deitcher

Support Cancer Ther· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases.
Steven R Deitcher, Raphael Ngengwe, Robert Kaplan, Howard Liebman, Karen Kaplan

Clin Adv Hematol Oncol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Goal-oriented thrombolytic therapy for venous thromboembolic disease.
Vijay Nambi, Marcelo P V Gomes, Steven R Deitcher

Clin Adv Hematol Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis